Evotec 566480, wohin geht die Reise??? (Seite 1606)
eröffnet am 12.01.07 11:23:52 von
neuester Beitrag 26.05.24 00:47:56 von
neuester Beitrag 26.05.24 00:47:56 von
Beiträge: 82.306
ID: 1.104.790
ID: 1.104.790
Aufrufe heute: 1.283
Gesamt: 16.310.479
Gesamt: 16.310.479
Aktive User: 0
ISIN: DE0005664809 · WKN: 566480 · Symbol: EVT
8,9500
EUR
-2,08 %
-0,1900 EUR
Letzter Kurs 24.05.24 Tradegate
Neuigkeiten
| TitelBeiträge |
|---|
| Evotec Aktien ab 5,80 Euro handeln - Ohne versteckte Kosten!Anzeige |
14:00 Uhr · wO Chartvergleich |
25.05.24 · HSBC Zertifikate Anzeige |
25.05.24 · wO Chartvergleich |
Werte aus der Branche Biotechnologie
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 0,6220 | +108,03 | |
| 2,1100 | +64,33 | |
| 55,50 | +36,03 | |
| 1,7870 | +28,56 | |
| 1,0500 | +23,53 |
| Wertpapier | Kurs | Perf. % |
|---|---|---|
| 1,7000 | -31,17 | |
| 2,6200 | -43,04 | |
| 0,7340 | -45,63 | |
| 1,0200 | -53,64 | |
| 3,7600 | -66,73 |
Beitrag zu dieser Diskussion schreiben
Feedback
Antwort auf Beitrag Nr.: 64.445.375 von Antarcticus am 17.07.20 10:35:42Ich hatte EVO in Besitz, konnte mich aber früh genug trennen! 
Antwort auf Beitrag Nr.: 64.445.138 von luxanleger am 17.07.20 10:22:43
Eben, keine Garantie! Royal Dutch hat dieses Jahr das erste Mal seit dem zweiten Weltkrieg die Dividende gekürzt.
Ich finde solche Empfehlungen wie du sie hier reinsetzt unpassend. Da es nicht das erste Mal ist und du nach deiner Statusangabe keine Evos im Besitz hast, hinterfrage ich einmal deine Motivation.
Aber genug "off topic", hier geht´s um Evo
Zitat von luxanleger:Zitat von Antarcticus: ...
Garantierst du mir diese Performance auch die nächsten zwei Jahre?
An der Börse gibt es keine Garantie, allerdings hat Sartorius bisher noch nie im Gewinnwachstum enttäuscht und das schon seit fast Jahrzehnten!
Eben, keine Garantie! Royal Dutch hat dieses Jahr das erste Mal seit dem zweiten Weltkrieg die Dividende gekürzt.
Ich finde solche Empfehlungen wie du sie hier reinsetzt unpassend. Da es nicht das erste Mal ist und du nach deiner Statusangabe keine Evos im Besitz hast, hinterfrage ich einmal deine Motivation.
Aber genug "off topic", hier geht´s um Evo
Antwort auf Beitrag Nr.: 64.445.138 von luxanleger am 17.07.20 10:22:43Im Prinzip wäre es am besten gewesen beide Aktien so 2010 zu kaufen.
Da waren einige 100% drinnen.
Jetzt wird es mit einigen 100% bei beiden Aktien sehr schwer, weil mitterweilen die Bewertung auch ambitioniert bei beiden ist!
Da waren einige 100% drinnen.
Jetzt wird es mit einigen 100% bei beiden Aktien sehr schwer, weil mitterweilen die Bewertung auch ambitioniert bei beiden ist!
Jungs, das Einzige auf das es im Leben eine Garantie gibt ist der Tod. Auch unser gesamtes Werteverständnis wird sich immer wieder modifizieren und anpassen.
Im Moment zeigt uns Corona die Grenzen und Fehler unseres aktuellen Systems auf. Was dann daraus resultiert, wird man sehen Ideen gibts ne Menge. :-)
VG
Im Moment zeigt uns Corona die Grenzen und Fehler unseres aktuellen Systems auf. Was dann daraus resultiert, wird man sehen Ideen gibts ne Menge. :-)
VG
Antwort auf Beitrag Nr.: 64.445.000 von Antarcticus am 17.07.20 10:14:24
An der Börse gibt es keine Garantie, allerdings hat Sartorius bisher noch nie im Gewinnwachstum enttäuscht und das schon seit fast Jahrzehnten!
Zitat von Antarcticus:Zitat von luxanleger: Wenn man vor zwei Jahren in Sartorius Stedim (95€) investiert hätte würde man sich jetzt (265€)
über ~ 180% Gewinn freuen....Du verstehst?!
Garantierst du mir diese Performance auch die nächsten zwei Jahre?
An der Börse gibt es keine Garantie, allerdings hat Sartorius bisher noch nie im Gewinnwachstum enttäuscht und das schon seit fast Jahrzehnten!
Trading Spotlight
Antwort auf Beitrag Nr.: 64.442.900 von luxanleger am 17.07.20 08:03:10
Garantierst du mir diese Performance auch die nächsten zwei Jahre?
Zitat von luxanleger: Wenn man vor zwei Jahren in Sartorius Stedim (95€) investiert hätte würde man sich jetzt (265€)
über ~ 180% Gewinn freuen....Du verstehst?!
Garantierst du mir diese Performance auch die nächsten zwei Jahre?
...denn bekanntlich ist die von Sanofi mit Evotec gentwickelte Diabetes Stammzellen Therapie bekanntlich vollständig auf Evotdc übergegangen
Eins und eins ergeben ????
Alles nur Spekulation und keine Handlungsanleitung.
In einer Mail an Evotec von vor einigen Wochen - nein hat nicht mein best buddy "Werner" beantwortet, sondern die liebe Frau Hansen - geht hervor, dass Stammzellen im Körper des Patienten ein "Device" brauchen, also einen "Behälter", um es vereinfacht zu sagen.
Es gibt verschiedene Hersteller solcher Devices
Evotec kennt die verschiedenen Ansätze
Evotec spricht mit den verschiedenen Device -Herstelles
So, nun die Dame, die das Projekt bei Sanofi begleitet hat in Verbindung zu Sernova.
Ich zähle da für mich eins und eins zusammen.
Viel Spaß bei der Recherche..
Eins und eins ergeben ????
Alles nur Spekulation und keine Handlungsanleitung.
In einer Mail an Evotec von vor einigen Wochen - nein hat nicht mein best buddy "Werner" beantwortet, sondern die liebe Frau Hansen - geht hervor, dass Stammzellen im Körper des Patienten ein "Device" brauchen, also einen "Behälter", um es vereinfacht zu sagen.
Es gibt verschiedene Hersteller solcher Devices
Evotec kennt die verschiedenen Ansätze
Evotec spricht mit den verschiedenen Device -Herstelles
So, nun die Dame, die das Projekt bei Sanofi begleitet hat in Verbindung zu Sernova.
Ich zähle da für mich eins und eins zusammen.
Viel Spaß bei der Recherche..
Hier eine News, die nur auf den zweiten Blick was mit Evotec zu tun hat.
Sernova bauen ein Device um Stammzellen im Körper des Patienten dauerhaft funktionieren zu lassen und sind damit bereits in der Klinik...
Bis zum Ende durchlesen und in der Vita der Dame sehen, wofür sie bisher verantwortlich war...
Dr. Anke M. Schulte Joins Sernova
Global Advisory Board
Veteran Pharmaceutical Executive in Regenerative Medicine Therapeutics to Contribute Corporate Development/ Strategic Expertise to Sernova
July 16, 2020
July 16, 2020 9:00 a.m. EDT
LONDON, ONTARIO – July 16, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage regenerative medicine company, announced today the creation of a Global Advisory Board, and the addition to the advisory board of Dr. Anke M. Schulte. Dr. Schulte is an internationally acclaimed expert in diabetes and cell therapy regenerative medicine and a 19-year veteran of Sanofi, a global pharmaceutical leader.
Sernova Global Advisory Board members will provide knowledge, experience and strategic insights to support the continued development and future commercialization of Sernova’s novel regenerative medicine cell therapy therapeutics platform. They will also provide advice on our clinical development programs, expansion plans for the Company, acquisition of additional technologies, as well as pharma collaborations and partnering.
Said Dr. Philip Toleikis, President and CEO of Sernova, “Through years of scientific teamwork, persistence and dedication, the Sernova team has developed, refined and systematically de-risked our cell therapy therapeutics platform by generating strong preclinical data and an expanding confirmatory human clinical data set for our implantable Cell Pouch™ device and immune protected cell technologies. We believe the new Global Advisory Board, which will include international experts who are visionary leaders, will help us in transforming the promise and potential of our platform into a ‘functional cure’ for a number of serious chronic diseases.”
Toleikis added, “As its inaugural member, Dr. Schulte brings an impressive career of excellence in innovation, experience and passion in the field, and importantly has witnessed the potential of Sernova’s diabetes technologies. Dr. Schulte’s 19 years of experience in progressive positions at Sanofi, in islet biology and in the regenerative medicine cell therapy field will be invaluable in contributing to our strategic decision making as we continue to advance our technologies to commercialization.”
“In the capacity of regenerative medicine lead with Sanofi, overseeing Type 1 diabetes-related collaborations and partnering, I have been closely following the preclinical and clinical advancements of Sernova’s novel cell therapy technology platform approach for a number of years. I am honored and thrilled to join Sernova’s Global Advisory Board as I believe Sernova is on the precipice of a ‘functional cure’ for several disease indications. I look forward to serving in this important and exciting new role while working alongside talented individuals and providing my expertise as these regenerative medicine products are commercialized,” remarked Dr. Anke M. Schulte.
Dr. Schulte’s recent career highlights and achievements at Sanofi:
Scientific Project Lead of Type 1 Diabetes (T1D) Collaborations within the Diabetes R&D unit
Leader of a Beta Cell Development Collaboration with Evotec A.G.
Project Head of the Sanofi Beta Cell Replacement Therapy program
Project Leader of the Innovative Medicines Initiative IMI2 private public partnership INNODIA: “Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes”
Head of the Islet Biology Cluster within the Diabetes R&D unit responsible for the development of novel innovative treatment modalities, including cell therapy
Dr. Schulte earned her PhD in Biochemistry at the Technical University of Darmstadt, Department of Chemistry, and was a Postdoctoral Fellow at Georgetown University. She joined Georgetown University, Department of Pharmacology Research Faculty and was then appointed Assistant Professor at the Lombardi Cancer Center at Georgetown University. In addition to being a pharmaceutical executive, Dr. Schulte is a scholar in her own right with over 30 peer reviewed top tier scientific publications/book chapters and has presented multiple peer reviewed presentations at international scientific symposia and conferences.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago.
ABOUT SERNOVA’S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial at the University of Chicago to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova’s clinical trial are incapable of producing c-peptide, a biomarker for insulin produced by islet cells.
Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, are transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made regarding the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further followed for one year to assess longer-term safety and efficacy.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Sernova bauen ein Device um Stammzellen im Körper des Patienten dauerhaft funktionieren zu lassen und sind damit bereits in der Klinik...
Bis zum Ende durchlesen und in der Vita der Dame sehen, wofür sie bisher verantwortlich war...
Dr. Anke M. Schulte Joins Sernova
Global Advisory Board
Veteran Pharmaceutical Executive in Regenerative Medicine Therapeutics to Contribute Corporate Development/ Strategic Expertise to Sernova
July 16, 2020
July 16, 2020 9:00 a.m. EDT
LONDON, ONTARIO – July 16, 2020 – Sernova Corp. (TSX-V:SVA)(OTCQB:SEOVF)(FSE:PSH), a clinical- stage regenerative medicine company, announced today the creation of a Global Advisory Board, and the addition to the advisory board of Dr. Anke M. Schulte. Dr. Schulte is an internationally acclaimed expert in diabetes and cell therapy regenerative medicine and a 19-year veteran of Sanofi, a global pharmaceutical leader.
Sernova Global Advisory Board members will provide knowledge, experience and strategic insights to support the continued development and future commercialization of Sernova’s novel regenerative medicine cell therapy therapeutics platform. They will also provide advice on our clinical development programs, expansion plans for the Company, acquisition of additional technologies, as well as pharma collaborations and partnering.
Said Dr. Philip Toleikis, President and CEO of Sernova, “Through years of scientific teamwork, persistence and dedication, the Sernova team has developed, refined and systematically de-risked our cell therapy therapeutics platform by generating strong preclinical data and an expanding confirmatory human clinical data set for our implantable Cell Pouch™ device and immune protected cell technologies. We believe the new Global Advisory Board, which will include international experts who are visionary leaders, will help us in transforming the promise and potential of our platform into a ‘functional cure’ for a number of serious chronic diseases.”
Toleikis added, “As its inaugural member, Dr. Schulte brings an impressive career of excellence in innovation, experience and passion in the field, and importantly has witnessed the potential of Sernova’s diabetes technologies. Dr. Schulte’s 19 years of experience in progressive positions at Sanofi, in islet biology and in the regenerative medicine cell therapy field will be invaluable in contributing to our strategic decision making as we continue to advance our technologies to commercialization.”
“In the capacity of regenerative medicine lead with Sanofi, overseeing Type 1 diabetes-related collaborations and partnering, I have been closely following the preclinical and clinical advancements of Sernova’s novel cell therapy technology platform approach for a number of years. I am honored and thrilled to join Sernova’s Global Advisory Board as I believe Sernova is on the precipice of a ‘functional cure’ for several disease indications. I look forward to serving in this important and exciting new role while working alongside talented individuals and providing my expertise as these regenerative medicine products are commercialized,” remarked Dr. Anke M. Schulte.
Dr. Schulte’s recent career highlights and achievements at Sanofi:
Scientific Project Lead of Type 1 Diabetes (T1D) Collaborations within the Diabetes R&D unit
Leader of a Beta Cell Development Collaboration with Evotec A.G.
Project Head of the Sanofi Beta Cell Replacement Therapy program
Project Leader of the Innovative Medicines Initiative IMI2 private public partnership INNODIA: “Translational approaches to disease modifying therapy of type 1 diabetes: an innovative approach towards understanding and arresting type 1 diabetes”
Head of the Islet Biology Cluster within the Diabetes R&D unit responsible for the development of novel innovative treatment modalities, including cell therapy
Dr. Schulte earned her PhD in Biochemistry at the Technical University of Darmstadt, Department of Chemistry, and was a Postdoctoral Fellow at Georgetown University. She joined Georgetown University, Department of Pharmacology Research Faculty and was then appointed Assistant Professor at the Lombardi Cancer Center at Georgetown University. In addition to being a pharmaceutical executive, Dr. Schulte is a scholar in her own right with over 30 peer reviewed top tier scientific publications/book chapters and has presented multiple peer reviewed presentations at international scientific symposia and conferences.
ABOUT SERNOVA CORP.
Sernova Corp is developing regenerative medicine therapeutic technologies using a medical device and immune protected therapeutic cells (i.e., human donor cells, corrected human cells and stem cell-derived cells) to improve the treatment and quality of life of people with chronic metabolic diseases such as insulin-dependent diabetes, blood disorders including hemophilia, and other diseases treated through replacement of proteins or hormones missing or in short supply within the body. For more information, please visit www.sernova.com.
ABOUT SERNOVA’S CELL POUCH SYSTEM
The Cell Pouch, as part of the Cell Pouch System, is a novel, proprietary, scalable, implantable macro- encapsulation device solution designed for the long-term survival and function of therapeutic cells. The device upon implantation is designed to incorporate with tissue, forming highly vascularized tissue chambers for the transplantation and function of therapeutic cells, which then release proteins and hormones as required to treat disease. The Cell Pouch, along with therapeutic cells, has been shown to provide long-term safety and efficacy in small and large animal models of diabetes and has been proven to provide a biologically compatible environment for insulin-producing cells in humans in a Canadian first-in-human study. Sernova is currently conducting a Phase I/II study at the University of Chicago.
ABOUT SERNOVA’S CLINICAL TRIAL
Sernova is conducting a Phase I/II non-randomized, unblinded, single-arm, company-sponsored trial at the University of Chicago to assess the safety and tolerability of islet transplantation into the company’s patented Cell Pouch in diabetic subjects with hypoglycemia unawareness. The secondary objective is to assess efficacy through a series of defined measures. Patients enrolled in Sernova’s clinical trial are incapable of producing c-peptide, a biomarker for insulin produced by islet cells.
Eligible subjects are implanted with Cell Pouches. Following the development of vascularized tissue chambers within the Cell Pouch, subjects are then stabilized on immunosuppression, and a dose of purified islets, under strict release criteria, are transplanted into the Cell Pouch.
A sentinel pouch is removed for an early assessment of the islet transplant. Subjects are followed for additional safety and efficacy measures for approximately six months. At this point, a decision is made regarding the transplant of a second islet dose with subsequent safety and efficacy follow up. Patients are then further followed for one year to assess longer-term safety and efficacy.
For more information on this clinical trial, please visit www.clinicaltrials.gov/ct2/show/NCT03513939. For more information on enrollment and recruitment details, please visit www.pwitkowski.org/sernova.
FOR FURTHER INFORMATION, PLEASE CONTACT:
Dominic Gray
Sernova Corp.
Tel: (519) 858-5126
dominic.gray@sernova.com
www.sernova.com
Antwort auf Beitrag Nr.: 64.442.759 von Trapos am 17.07.20 07:43:57Wenn man vor zwei Jahren in Sartorius Stedim (95€) investiert hätte würde man sich jetzt (265€)
über ~ 180% Gewinn freuen....Du verstehst?!
über ~ 180% Gewinn freuen....Du verstehst?!
Na, ja vor zwei Jahren standen wir im Sommer um die 16,50 bis 17 Euro.
Wenn man mit genug Kapital 40% macht ist das nicht so schlecht für einen "Loser".
Wobei wenn man Schicksale im Leben als Loser bezeichnet hat das für mich einen fahlen Beigeschmack!
Wenn man mit genug Kapital 40% macht ist das nicht so schlecht für einen "Loser".
Wobei wenn man Schicksale im Leben als Loser bezeichnet hat das für mich einen fahlen Beigeschmack!
Durchsuchen
14:00 Uhr · wO Chartvergleich · Carl Zeiss Meditec |
25.05.24 · wO Chartvergleich · ABB |
24.05.24 · wO Newsflash · American Express |
24.05.24 · BörsenNEWS.de · Advanced Micro Devices |
23.05.24 · wO Newsflash · Carl Zeiss Meditec |
23.05.24 · kapitalerhoehungen.de · Evotec |
22.05.24 · dpa-AFX · Analog Devices |